Related Experiment Videos
Development of a rapid and ultrasensitive RIA method for estrogen (E2, E1, E1-S) determination with selective solid
A Martinetti1, E Seregni, E Bajetta
1Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Abstract:
The inhibition of the proliferative stimulation exercised by estrogens on neoplastic cells is the goal of all endocrine therapies in breast cancer. Under various circumstances, e.g. with the use of aromatase inhibitors, this result can be obtained by blocking the synthetic pathway and, consequently, by lowering the circulating levels of estradiol (E2), estrone (E1), and estrone sulfate (E1-S). The evaluation of these hormones in plasma could therefore represent a useful indicator of the biological efficacy of the therapy. However, the measurement of circulating steroids in a large series of patients is often a complicated procedure. Indirect methods of extraction are time consuming and expensive while the analytical sensitivity of direct methods is not sufficient to measure the residual levels of E2, E1, and E1-S. In this paper we describe a novel extraction method for the evaluation of plasma levels of E2, E1, and E1-S. This new method consists of solid phase extraction followed by a highly specific radioimmunoassay. The sensitivity of the assay is 0.6 pg/ml, 2.0 pg/ml and 7.0 pg/ml for E2, E1, and E1-S, respectively.
Insights
A new method accurately measures estrogen levels (estradiol, estrone, estrone sulfate) in breast cancer patients undergoing endocrine therapy. This aids in assessing treatment effectiveness by quantifying residual hormones with high sensitivity.
Area of Science:
- Endocrinology
- Oncology
- Analytical Chemistry
Background:
- Endocrine therapy for breast cancer aims to inhibit estrogen's proliferative effect on neoplastic cells.
- Aromatase inhibitors lower circulating estradiol (E2), estrone (E1), and estrone sulfate (E1-S) by blocking synthesis.
- Measuring these hormones can indicate therapy efficacy, but current methods are challenging.
Purpose of the Study:
- To develop a novel, sensitive, and efficient method for measuring plasma E2, E1, and E1-S levels.
- To provide a reliable indicator for assessing the biological efficacy of endocrine therapy in breast cancer patients.
Main Methods:
- A novel extraction method involving solid-phase extraction was developed.
- The extracted samples were analyzed using a highly specific radioimmunoassay.
- The method was validated for sensitivity in measuring E2, E1, and E1-S.
Main Results:
- The novel method demonstrated high sensitivity for E2 (0.6 pg/ml), E1 (2.0 pg/ml), and E1-S (7.0 pg/ml).
- This allows for the measurement of residual hormone levels previously difficult to quantify.
- The method offers a more practical approach for evaluating therapy efficacy in large patient cohorts.
Conclusions:
- The described solid-phase extraction followed by radioimmunoassay is a sensitive and specific method for quantifying plasma E2, E1, and E1-S.
- This technique can serve as a valuable tool for monitoring endocrine therapy response in breast cancer.
- Improved measurement of hormone levels can lead to better patient management and treatment optimization.